A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy

Journal of Surgical Oncology

Volumn 109, Issue 8, 2014, Pages 764-769

  Matsuda, Naoko ^a   Hayashi, Naoki ^a   Ohde, Sachiko ^b   Yagata, Hiroshi ^a   Kajiura, Yuka ^a   Yoshida, Atsushi ^a   Suzuki, Koyu ^a   Nakamura, Seigo ^c   Tsunoda, Hiroko ^a   Yamauchi, Hideko ^a  

^a ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^b St Luke's Life Science Institute   (Japan)

^c SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

breast cancer; breast conserving therapy; locoregional recurrence; neoadjuvant chemotherapy; nomogram

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; TRASTUZUMAB;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BOOTSTRAPPING; BREAST BIOPSY; BREAST CANCER; CALIBRATION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; FEMALE; HUMAN; LOCOREGIONAL RECURRENCE; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NOMOGRAM; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE; REPRODUCIBILITY; RETROSPECTIVE STUDY;

BREAST CANCER; BREAST-CONSERVING THERAPY; LOCOREGIONAL RECURRENCE; NEOADJUVANT CHEMOTHERAPY; NOMOGRAM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NOMOGRAMS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; ROC CURVE; SURVIVAL RATE; TAXOIDS;

EID: 84900524379     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23586     Document Type: Article

References (24)

1. Cunningham JD, Weiss SE, Ahmed S, et al.: The efficacy of neoadjuvant chemotherapy compared to postoperative therapy in the treatment of locally advanced breast cancer. Cancer Invest 1998; 16: 80-86.
2. Fisher B, Brown A, Mamounas E, et al.: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15: 2483-2493.
3. Powles TJ, Hickish TF, Makris A, et al.: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995; 13: 547-552.
4. Boughey JC, Peintinger F, Meric-Bernstam F, et al.: Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg 2006; 244: 464-470.
5. Rouzier R, Extra JM, Klijanienko J, et al.: Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002; 20: 1304-1310.
6. Kuerer HM, Newman LA, Smith TL, et al.: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
7. Broet P, Scholl SM, de la Rochefordiere A, et al.: Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: An updated analysis of a randomized trial. Breast Cancer Res Treat 1999; 58: 151-156.
8. Calais G, Berger C, Descamps P, et al.: Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3-cm. Cancer 1994; 74: 1283-1288.
9. Perloff M, Lesnick GJ, Korzun A, et al.: Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: A Cancer and Leukemia Group B study. J Clin Oncol 1988; 6: 261-269.
10. Rouzier R, Extra JM, Carton M, et al.: Primary chemotherapy for operable breast cancer: Incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol 2001; 19: 3828-3835.
11. Smith IE, Lipton L:, Preoperative/neoadjuvant medical therapy for early breast cancer. Lancet Oncol 2001; 2: 561-570.
12. Touboul E, Lefranc JP, Blondon J, et al.: Primary chemotherapy and preoperative irradiation for patients with stage II larger than 3-cm or locally advanced non-inflammatory breast cancer. Radiother Oncol 1997; 42: 219-229.
13. Chen AM, Meric-Bernstam F, Hunt KK, et al.: Breast conservation after neoadjuvant chemotherapy: The MD Anderson cancer center experience. J Clin Oncol 2004; 22: 2303-2312.
14. Mauri D, Pavlidis N, Ioannidis JP:, Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst 2005; 97: 188-194.
15. Cebrecos I, Cordoba O, Deu J, et al.: Can we predict local recurrence in breast conserving surgery after neoadjuvant chemotherapy ? Eur J Surg Oncol 2010; 36: 528-534.
16. Rastogi P, Anderson SJ, Bear HD, et al.: Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-785.
17. Tiezzi DG, Andrade JM, Marana HR, et al.: Breast conserving surgery after neoadjuvant therapy for large primary breast cancer. Eur J Surg Oncol 2008; 34: 863-867.
18. Ellis P, Smith I, Ashley S, et al.: Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 1998; 16: 107-114.
19. Esserman LJ, Berry DA, DeMichele A, et al.: Pathologic complete response predict recurrence-free survival more effectively by cancer subset: Results from the I-SPY 1 TRIAL-CALGB150007/150012, ACRIN 6657. J Clin Oncol 2012; 30: 3242-3249.
20. Akay CL, Meric-Bernstam F, Hunt KK, et al.: Evaluation of the MD Anderson prognostic index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol 2012; 19: 901-907.
21. Rouzier R, Pusztai L, Delaloge S, et al.: Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 2005; 23: 8331-8339.
22. Beriwal S, Schwartz GF, Komarnicky L, et al.: Breast-conserving therapy after neoadjuvant chemotherapy: Long-term results. Breast J 2006; 12: 159-164.
23. Gianni L, Eiermann W, Semiglazov V, et al.: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375: 377-384.
24. Mamounas EP, Anderson SJ, Dignam JJ, et al.: Predictors of locoregional recurrence after neoadjuvant chemotherapy: Results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 2012; 30: 3960-3966.